Brief: Transgene To Present New Positive Preliminary Phase I Data On Tg4050 At AACR 2022
09/03/2022 07:09
March 9 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE TO PRESENT NEW POSITIVE PRELIMINARY PHASE I DATA
ON
TG4050 (MYVAC® PLATFORM), ITS INDIVIDUALIZED THERAPEUTIC CANCER
VACCINE, AT AACR 2022
Source text for Eikon: ID:nBw26RY62a
Further company coverage: TRNG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs